Investigators with The Cancer Genome Atlas Research Network discovered genomic differences in head and neck cancers caused by infection with the human papillomavirus. Researchers also uncovered new smoking-related cancer subtypes and potential new drug targets, and found numerous genomic similarities with other cancer types.
An analysis comparing sentinel lymph node biopsy procedures using Lymphoseek (technetium Tc 99m tilmanocept) injection and vital blue dye to filtered sulfur colloid and VBD in breast cancer patients showed that Lymphoseek patients had significantly fewer sentinel lymph nodes removed per procedure (mean: 1.85 vs. 3.24; p < 0.0001).
Decades after undergoing cranial irradiation for childhood cancer, researchers at St. Jude Children’s Research Hospital found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. The study included 748 St. Jude survivors of leukemia, brain and other cancers whose treatment included brain... […]
Researchers found that a newer member of the taxane family, cabazitaxel, has properties that could make it more effective for some prostate cancer patients.Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.
Treatment with Imbruvica (ibrutinib) was associated with an 88 percent overall response rate, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory high-risk chronic lymphocytic leukemia in studies ranging from phase II to III.
Patients with indolent non-Hodgkin's lymphoma lived significantly longer without disease worsening or death when treated with Gazyva (obinutuzumab) plus bendamustine and followed by Gazyva alone, compared to bendamustine alone.
FDA approved Opdivo (nivolumab) injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase II study of CPX-351 in adult patients with first-relapse acute myeloid leukemia demonstrated clinical benefit in patients with poor-risk disease as defined by the European Prognostic Index.
Top-line results of the phase III MARIANNE study evaluated three HER2-targeted regimens—Kadcyla (ado-trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy—in people with previously untreated advanced HER2-positive breast cancer.
